Exacis Biotherapeutics Presents Data on its Stealth mRNA-Engineered NK-cell Platform at American Society of Gene & Cell Therapy Annual Meeting
Share this article Share this article CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to democratize access to the most advanced and effective cancer treatments, revealed key data related to its engineered iPSC-derived NK-cell platform at the American Society of Gene & Cell Therapy 24th Annual Meeting. These data include the successful generation of functional NK cells from iPSCs engineered to contain a biallelic knockout of a key MHC class I gene. Exacis' cell engineering strategy is designed to allow its E...
Source: prnewswire.com